Alaunos Therapeutics Stock Market Value
| TCRT Stock | USD 2.57 0.04 1.53% |
| Symbol | Alaunos |
Is there potential for Biotechnology market expansion? Will Alaunos introduce new products? Factors like these will boost the valuation of Alaunos Therapeutics. If investors know Alaunos will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Alaunos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.30) | Revenue Per Share | Quarterly Revenue Growth 1 | Return On Assets | Return On Equity |
Understanding Alaunos Therapeutics requires distinguishing between market price and book value, where the latter reflects Alaunos's accounting equity. The concept of intrinsic value - what Alaunos Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Alaunos Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Alaunos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alaunos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Alaunos Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Alaunos Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Alaunos Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Alaunos Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Alaunos Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Alaunos Therapeutics or generate 0.0% return on investment in Alaunos Therapeutics over 90 days. Alaunos Therapeutics is related to or competes with Cyclerion Therapeutics, Pasithea Therapeutics, Vyne Therapeutics, Quoin Pharmaceuticals, Addex Therapeutics, Polyrizon, and AIM ImmunoTech. Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-c... More
Alaunos Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Alaunos Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Alaunos Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.75 | |||
| Information Ratio | 0.0216 | |||
| Maximum Drawdown | 24.31 | |||
| Value At Risk | (10.55) | |||
| Potential Upside | 10.07 |
Alaunos Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alaunos Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Alaunos Therapeutics' standard deviation. In reality, there are many statistical measures that can use Alaunos Therapeutics historical prices to predict the future Alaunos Therapeutics' volatility.| Risk Adjusted Performance | 0.0355 | |||
| Jensen Alpha | 0.087 | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | 0.0225 | |||
| Treynor Ratio | 0.1109 |
Alaunos Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0355 | |||
| Market Risk Adjusted Performance | 0.1209 | |||
| Mean Deviation | 4.7 | |||
| Semi Deviation | 5.56 | |||
| Downside Deviation | 5.75 | |||
| Coefficient Of Variation | 3000.62 | |||
| Standard Deviation | 5.98 | |||
| Variance | 35.72 | |||
| Information Ratio | 0.0216 | |||
| Jensen Alpha | 0.087 | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | 0.0225 | |||
| Treynor Ratio | 0.1109 | |||
| Maximum Drawdown | 24.31 | |||
| Value At Risk | (10.55) | |||
| Potential Upside | 10.07 | |||
| Downside Variance | 33.11 | |||
| Semi Variance | 30.96 | |||
| Expected Short fall | (5.20) | |||
| Skewness | 0.1114 | |||
| Kurtosis | (0.40) |
Alaunos Therapeutics Backtested Returns
Alaunos Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0343, which signifies that the company had a -0.0343 % return per unit of standard deviation over the last 3 months. Alaunos Therapeutics exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Alaunos Therapeutics' mean deviation of 4.7, and Risk Adjusted Performance of 0.0355 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.71, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Alaunos Therapeutics will likely underperform. At this point, Alaunos Therapeutics has a negative expected return of -0.2%. Please make sure to confirm Alaunos Therapeutics' downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if Alaunos Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.26 |
Weak reverse predictability
Alaunos Therapeutics has weak reverse predictability. Overlapping area represents the amount of predictability between Alaunos Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Alaunos Therapeutics price movement. The serial correlation of -0.26 indicates that nearly 26.0% of current Alaunos Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.26 | |
| Spearman Rank Test | -0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 0.07 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alaunos Stock Analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.